Kawanishi Hideki, Nakayama Masaaki, Miyazaki Masanobu, Honda Kazuho, Tomo Tadashi, Kasai Kenji, Nakamoto Hidetomo
Tsuchiya General Hospital, Hiroshima, Japan.
Adv Perit Dial. 2010;26:71-4.
Many observational studies have been conducted on the occurrence of encapsulating peritoneal sclerosis (EPS). However, poorly biocompatible acidic glucose-based dialysis solutions were used in all previous studies. Today, dialysis solutions that are more biocompatible have become widely available. We therefore initiated a new prospective observational study on the occurrence of EPS. The study design is based on that of a previous study conducted in Japan that used solutions high in glucose degradation products (GDPs). Patients undergoing dialysis with a low-GDP dialysis solution, which is considered to show excellent biocompatibility, will be followed for 4 years, and the study will evaluate withdrawal from peritoneal dialysis, incidence of EPS, and factors related to EPS occurrence with the new dialysis solution. This study is expected to clarify the effects of biocompatible dialysis solutions.
关于包裹性腹膜硬化(EPS)的发生,已经开展了许多观察性研究。然而,此前所有研究均使用了生物相容性较差的酸性葡萄糖基透析液。如今,生物相容性更好的透析液已广泛可得。因此,我们启动了一项关于EPS发生情况的新的前瞻性观察性研究。该研究设计基于此前在日本进行的一项研究,该研究使用了葡萄糖降解产物(GDPs)含量高的溶液。使用被认为具有优异生物相容性的低GDP透析液进行透析的患者将被随访4年,该研究将评估腹膜透析的退出情况、EPS的发生率以及与使用新透析液发生EPS相关的因素。这项研究有望阐明生物相容性透析液的作用。